Acoustic metamaterials-driven transdermal drug delivery for rapid and on-demand management of acute disease

Junhua Xu, Hongwei Cai, Zhuhao Wu, Xiang Li, Chunhui Tian, Zheng Ao, Vivian C. Niu, Xiao Xiao, Lei Jiang, Marat Khodoun, Marc Rothenberg, Ken Mackie, Jun Chen (), Luke P. Lee () and Feng Guo ()
Additional contact information
Junhua Xu: Indiana University
Hongwei Cai: Indiana University
Zhuhao Wu: Indiana University
Xiang Li: Indiana University
Chunhui Tian: Indiana University
Zheng Ao: Indiana University
Vivian C. Niu: Indiana University
Xiao Xiao: University of California, Los Angeles
Lei Jiang: Indiana University
Marat Khodoun: University of Cincinnati
Marc Rothenberg: University of Cincinnati
Ken Mackie: Indiana University
Jun Chen: University of California, Los Angeles
Luke P. Lee: Brigham and Women’s Hospital, Harvard Medical School
Feng Guo: Indiana University

Nature Communications, 2023, vol. 14, issue 1, 1-9

Abstract: Abstract Transdermal drug delivery provides convenient and pain-free self-administration for personalized therapy. However, challenges remain in treating acute diseases mainly due to their inability to timely administrate therapeutics and precisely regulate pharmacokinetics within a short time window. Here we report the development of active acoustic metamaterials-driven transdermal drug delivery for rapid and on-demand acute disease management. Through the integration of active acoustic metamaterials, a compact therapeutic patch is integrated for penetration of skin stratum corneum and active percutaneous transport of therapeutics with precise control of dose and rate over time. Moreover, the patch device quantitatively regulates the dosage and release kinetics of therapeutics and achieves better delivery performance in vivo than through subcutaneous injection. As a proof-of-concept application, we show our method can reverse life-threatening acute allergic reactions in a female mouse model of anaphylaxis via a multi-burst delivery of epinephrine, showing better efficacy than a fixed dosage injection of epinephrine, which is the current gold standard ‘self-injectable epinephrine’ strategy. This innovative method may provide a promising means to manage acute disease for personalized medicine.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-023-36581-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-36581-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-36581-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().